50738-63-1

Basic information

• Product Name: (1r,4r)-methyl 4-(aminomethyl)cyclohexanecarboxylate
• Synonyms: (1r,4r)-methyl 4-(aminomethyl)cyclohexanecarboxylate;trans-Methyl 4-(aMinoMethyl)cyclohexanecarboxylate
• CAS NO: 50738-63-1
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.23678
• Mol File: 50738-63-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 240.7°C at 760 mmHg
• Flash Point: 106.2°C
• Appearance: /
• Density: 1.014g/cm³
• Vapor Pressure: 0.0373mmHg at 25°C
• Refractive Index: 1.467
• PKA: 10.27±0.29(Predicted)
• CAS DataBase Reference: (1r,4r)-methyl 4-(aminomethyl)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4r)-methyl 4-(aminomethyl)cyclohexanecarboxylate(50738-63-1)
• EPA Substance Registry System: (1r,4r)-methyl 4-(aminomethyl)cyclohexanecarboxylate(50738-63-1)

Safety Data

• Hazardous Substances Data: 50738-63-1(Hazardous Substances Data)

Usage

General Description

"(1r,4r)-Methyl 4-(aminomethyl)cyclohexanecarboxylate" is a chemical compound that is significant in the field of biochemistry and synthetic organic chemistry. It contains functional groups of an amino group (-NH2), a methyl group (-CH3), and a carboxylate ester (-COO-), attached to a cyclohexane ring, which is a six-carbon cyclic molecule. Due to its structural similarity to amino acids, this compound may play a role in peptide synthesis, possibly acting as an amino acid surrogate or building block. However, detailed information about its applications and properties, like toxicity, reactivity, or biosynthesis, is scarce in the available literature.

InChI:InChI=1/C9H17NO2/c1-12-9(11)8-4-2-7(6-10)3-5-8/h7-8H,2-6,10H2,1H3

Upstream product

• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 67-56-1 methanol 

Downstream Products

• 1402008-44-9 trans-4-{2-[(2-methoxy-ethyl)-methyl-amino]-7-methyl-8-oxo-7,8-dihydro-purin-9-ylmethyl}-cyclohexane lithium carboxylate 
• 1402008-32-5 trans-4-{5-[(2-dimethylamino-ethyl)-methyl-amino]-1-methyl-2-oxo-1,2-dihydro-imidazo[4,5-b]pyridin-3-ylmethyl}-cyclohexane lithium carboxylate 
• 1312812-89-7 [trans-4-({[(2-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}quinolin-4-yl)carbonyl]amino}methyl)cyclohexyl]methyl tert-butylcarbamate 
• 1312812-91-1 methyl trans-4-({[(2-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}quinolin-4-yl)carbonyl]amino}methyl)cyclohexanecarboxylate 
• 180532-48-3 Methyl trans-4-[N-(phenylsulphonyl)-aminomethyl]-cyclohexanecarboxylate 

Relevant articles and documents

Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors

Currently, synergistic inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) and histone deacetylases (HDACs) has been a potential effective strategy for cancer treatment. Herein, by combining critical pharmacophores in approved drugs olaparib and chidamid

METHOD OF PREPARING DENDRITIC DRUGS

Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.

Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation

The present invention relates to piperazine derivatives of the general formula STR1 in which Ra, Y1 to Y3 and E are defined herein, tautomers thereof, stereoisomers thereof, including their mixtures, and salts thereof, and in particular physiologically tolerated salts thereof with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, such as aggregation-inhibiting activity. This invention also relates to medicaments comprising these compounds and to processes for the preparation of these compounds.